Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Pancragen 20 mg
Pancragen 20 mg

Pancragen 20 mg

Pancragen 20 mg is a synthetic short regulatory peptide belonging to the family of tissue-specific bioregulators developed by the Khavinson school (Endogenic line); it is traditionally associated with the tetrapeptide Lys-Glu-Asp-Trp (KEDW) and linked to the pancreas, and is supplied as a vial containing a lyophilized powder for self-reconstitution.

37,99 €
With code BLACK: 30,39 € Lowest price in the 30 days before the discount: 37,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
View the laboratory analysis report Peptide Calculator

Pancragen 20 mg - pancreatic bioregulator peptide

  • Pancragen 20 mg to syntetyczny krótki peptyd regulatorowy z rodziny tkankowo-specyficznych bioregulatorów szkoły Khavinsona (linia Endogenic), tradycyjnie wiązany z tetrapeptydem Lys-Glu-Asp-Trp (KEDW) i przypisywany trzustce — dostarczany jako fiolka z liofilizatem do samodzielnej rekonstytucji.
  • Research context: peptide bioregulation of pancreatic cells, secretory function and cell protection in models.
  • Research Use Only reagent

As a research reagent, Pancragen has never been registered as a medicinal product in the EU, US or other jurisdiction. It should be clearly distinguished from Superfort (Pancramin) – a peptide preparation distributed as a commercial product in Russia as part of the Cytomax line, derived from the concept of pancreatic bioregulation. Suprefort is a separate regulatory entity in a specific jurisdiction; Pancragen in reagent circulation – in lyophilized vial format – is a Research Use Only material and it is not a replacement.

More importantly, a pancreatic bioregulator peptide it is not insulin or a cure for diabetes and does not replace a medicinal product or medical consultation. No EMA/FDA authorization as a medicine and no EFSA authorization as a dietary supplement ingredient. Marketing a product as a “pancreatic peptide”, “sugar level support”, “natural glycemic control” or “diabetes peptide” is contrary to the Research Use Only framework.

Pancragen is a synthetic short regulatory peptide derived from concept peptide bioregulation developed in St. Petersburg Institute of Bioregulation and Gerontology under the supervision of Vladimir Khavinson. In this research school, Pancragen belongs to the family of tissue-specific regulatory peptides (nomenclature ending in “-gene”), traditionally associated with a tetrapeptide with the sequence Lys-Glu-Asp-Trp (KEDW). The conceptual assumption of the entire group is that short, several-amino acid peptides have affinity for the tissue from which they were originally isolated or to which their design concerns – in the case of Pancragen, it is the pancreas (cells of the islets of Langerhans and cells of the exocrine part).

The reagent belongs to the line Endogenous — materials mapping molecules of endogenous origin or directly derived from them, provided for research on peptide bioregulation of pancreatic tissue. This reagent is supplied by Pancragen in the format 20 mg lyophilized vials, which the researcher independently reconstitutes before work. The lyophilized format ensures long stability of the peptide before dissolution and leaves the researcher full freedom to select the solvent and working concentration according to the parameters of the planned experiment.

Once reconstituted, the peptide can be considered in the routes of administration studied for short regulatory peptides – intranasal or subcutaneous in in vivo models. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

Peptide bioregulation in the Khavinson school

The concept of peptide bioregulation is based on the observation that short peptides composed of two to four amino acid residues can influence cell function in a tissue-specific manner. In a series of works (Khavinson 2002; Anisimov, Khavinson 2010), Vladimir Khavinson and colleagues hypothesized that these types of peptides are part of an internal regulatory system that controls gene expression in response to the functional state and age of the tissue.

Within this concept, the entire family was distinguished research peptides assigned to specific organs: pineal gland, thymus, vessels, heart, liver, bronchi, prostate – and pancreas, for which the working name has become Pancragen. Mechanistically, this school proposes that short regulatory peptides enter the cell and then interact with specific sites in the DNA strand or with proteins that regulate transcription, thereby modulating the expression of genes relevant to a given cell type.

In tissue culture models, the influence of peptides of this family on the proliferation and differentiation of cells derived from the “mother” tissue of the peptide was observed (Chalisova et al. 2015 – tissue-specific peptide effects). The tissue specificity hypothesis is one of the most distinctive – and at the same time most controversial – elements of this concept, because it requires a mechanism for tissue recognition by a very short peptide sequence. More broadly, the Khavinson family of short regulatory peptides includes several recurring research themes:

  • Tissue-specific modulation of gene expression — hypothesis of the interaction of short peptides with DNA sequences and transcription factors
  • Effect on cell proliferation and differentiation in tissue cultures derived from the “parent” organ of the peptide
  • Cytoprotective and antioxidant effects in cell models subjected to stress (oxidative, metabolic)
  • Gerontological context — peptides as hypothetical modulators of processes related to tissue aging (Khavinson 2002; Anisimov, Khavinson 2010)
  • Short sequence and low molecular weight — tetra- and tripeptides, designed as fragments of larger tissue regulators

Pancragen takes the place of a peptide in this family tissue-specific for the pancreas — tools to study the concept of peptide bioregulation of the pancreatic cell, its secretory function, protection and regeneration in experimental models. The same organ-specific logic is reflected in related line bioregulators: Livagen for the liver, Cardiogen for heart tissue, Bronchogen for the bronchopulmonary epithelium and Prostamax for the prostate.

In the same line of organ bioregulators, the literature of the bioregulation school also considers Superfort (Pancramin) – A preparation with commercial status in Russia that should not be confused with a research reagent (distinction discussed below).

What is Pancragen?

Chemically, Pancragen is traditionally associated with a linear tetrapeptide with the sequence Lys-Glu-Asp-Trp. In vial format it is supplied as a lyophilisate (powder) for self-reconstitution.

  • Common name: Pancragen, pancreatic bioregulator peptide, pancreatic peptide
  • Sequence (traditionally assigned): Lys-Glu-Asp-Trp (KEDW) — lysyl-glutamyl-asparaginyl-tryptophan; sequence for verification in the batch COA
  • Chemical class: synthetic short regulatory peptide (tetrapeptide); family of bioregulator peptides of the Khavinson school, tissue-specific lineage for the pancreas
  • CAS number: for verification in the batch COA
  • Molar mass: dependent on confirmed sequence; for the KEDW variant of approximately 575–590 g/mol (indicative value – the mass from the MS analysis of the batch is binding)
  • Delivered form: white or cream lyophilisate (powder) in a vial, peptide content 20 mg; for reconstitution with solvent before work; purity ≥98% HPLC
  • Conceptual origin: Khavinson’s concept of peptide bioregulation (St. Petersburg Institute of Bioregulation and Gerontology); Endogenic line; commercial equivalent: Suprefort / Pancramin (Cytomax, Russia)

Characteristics table

Parameter Value Attention
Sequence Lys-Glu-Asp-Trp (KEDW) traditionally assigned – for verification in the COA
CAS number for verification in the batch COA identity is decided by the party’s MS
Molar mass approx. 575–590 g/mol (KEDW variant) indicative value; the MS mass is binding
Class pancreatic regulatory tetrapeptide Khavinson bioregulator family
Character white/cream lyophilisate (powder) 20 mg vial, for reconstitution
Peptide content 20 mg per vial declared value, in COA
Cleanliness ≥98% HPLC UV detection, per batch verification
Commercial equivalent Suprefort / Pancramin (Russia) separate regulatory entity – not this reagent

Origin: Pancragen originates from the tissue-specific peptide research program conducted at St. Petersburg Institute of Bioregulation and Gerontology. As part of this program, peptides were designed as short regulatory fragments assigned to specific organs, and then their effect on cells of a given tissue was examined in cultures and in animal models. Pancragen was assigned to the pancreas – both to the cells of the endocrine part (islet of Langerhans) and the exocrine part.

It should be emphasized that the exact sequence and chemical identity of peptides of this family in the reagent trade may be inconsistent – therefore the sequence and molar mass of each batch of Pancragen require confirmation in a certificate of analysis (COA), and the KEDW sequence is given as traditionally assigned, not as an unconditionally established identity of each material on the market.

Mechanism of action at the molecular level

Pancragen is considered in the literature through the prism of the concept of tissue-specific peptide bioregulation. The following description refers to hypotheses and observations from preclinical models – not to a validated human clinical mechanism. Profile observed and postulated in preclinical models:

  1. Tissue-specific peptide bioregulation of pancreatic cells — the central hypothesis of the Khavinson school assumes that short regulatory peptides enter the cell and modulate gene expression by interacting with specific DNA sequences or with the transcription apparatus. In the case of Pancragen, this concerns genes important for the function, survival and differentiation of islet of Langerhans cells and exocrine cells. Mechanism: postulated modulation of transcription, not classic stimulation of the membrane receptor (Khavinson 2002; Khavinson et al. 2021 – short peptides regulate gene expression)
  2. Modulation of pancreatic secretory function in models — in tissue culture models and in animal models, the influence of peptides of this family on the secretion parameters of pancreatic cells was studied: digestive enzymes in the exocrine part and markers of glycemic regulation in the endocrine part; the research context is the normalization of secretory function in experimental conditions, not the therapeutic effect in humans (Kuznik et al. 2020 – peptide bioregulators)
  3. Antioxidant and anti-inflammatory effects — the protective potential of the peptide against cellular damage was tested in models of pancreatic tissue subjected to oxidative or metabolic stress; the research context includes the protection of cells against reactive oxygen species and the modulation of inflammatory markers in pancreatic tissue
  4. Support for cell regeneration and protection in models — postulated impact on the survival and renewal of pancreatic cells, tested in culture models and tissue damage models as part of the general concept of organ bioregulation

Characteristics of peptides of this family (based on the literature of the bioregulation school):

  • Short sequence (tetrapeptide) and low molecular weight – typical for the designed regulatory fragments
  • Postulated ability to penetrate the cell and interact at the nuclear level – a hypothesis requiring further mechanistic verification
  • The action is described as modulatory and contextual, rather than classically stimulating – the peptide is intended to “normalize” cell function, not to force a one-way response
  • Human pharmacokinetic profile: not characterized for the reagent; no data from randomized clinical trials

Important distinction - Russian school, Pancragen vs Suprefort, peptide vs insulin

Three distinctions are critical here and must not be merged into one.

First – data origin. The concept of tissue-specific peptide bioregulation is an original, consistently developed achievement Russian scientific school (St. Petersburg Institute of Bioregulation and Gerontology). It is characterized by limited independent replication outside its home centers and much of the literature in Russian. The data for Pancragen comes from cell and animal models – not large randomized clinical trials. This does not disqualify the concept, but sets a limit for interpretation: the observations are preliminary and require confirmation.

Second – Pancragen (RUO reagent) vs. Suprefort (commercial preparation). These are two separate regulatory entities. Superfort (Pancramin) is a peptide preparation distributed as a commercial product in Russia as part of the Cytomax line, derived from the concept of pancreatic bioregulation. Pancragen in the reagent trade, it is a Research Use Only material – a chemical reagent for laboratory research, without registration as a drug in the EU, USA or other jurisdiction. Pancragen RUO reagent is not a replacement Suprefort and does not replace medical consultation or medicinal product.

Third – bioregulator peptide vs. insulin and diabetes drugs. This distinction is most important from a security point of view. Pancragen is considered in models as a hypothetical modulator of pancreatic cell function – it is not insulin, it is not an incretin analogue, it is not an oral antidiabetic drug and has no proven effect on lowering blood sugar levels in humans.

Observations regarding “glycemic regulation” come only from preclinical models and describe cellular parameters, not clinical effects. Pancragen is not a substitute insulin or any diabetes medication and does not replace therapy conducted under medical supervision. The material remains a research reagent with no human use.

Applications in scientific research

Pancragen in the format of a lyophilized vial is used as a reagent in research work on the concept of peptide bioregulation of tissue-specific pancreatic tissue. The lyophilisate allows the researcher to reconstitute the material himself and select the working concentration for his protocol. In vitro models (pancreatic cell cultures, islets of Langerhans cultures, oxidative and metabolic stress models) examine the effect of the peptide on cell viability, secretory parameters, differentiation, and markers of oxidative damage and inflammation.

In vivo models (animal models used by bioregulation centers) examined the influence of peptides of this family on tissue parameters related to the secretory function, protection and aging of pancreatic tissue. Specific research directions include:

  • The concept of peptide tissue bioregulation — Pancragen as a model tissue-specific peptide for the pancreas; testing the hypothesis of modulation of gene expression by short peptides in pancreatic cells
  • Models of secretory function — assessment of the effect of the peptide on the parameters of secretion of digestive enzymes in the exocrine part and on markers of glycemic regulation in the endocrine part in culture conditions
  • Cytoprotection models — assessment of the protective potential against oxidative and metabolic stress in pancreatic cell cultures
  • Tissue regeneration studies — effect of the peptide on the survival, renewal and differentiation of pancreatic cells in culture and injury models
  • Experimental gerontology — bioregulatory peptides as tools for studying processes related to the aging of organ tissue (Anisimov, Khavinson 2010)
  • Independent and methodological verification — replication of observations of the bioregulation school in independent laboratories, including confirmation of the chemical identity and sequence of the tested material

REGULATORY STATUS

Pancragen falls under class S0 of the WADA Prohibited List (non-approved substances) as a compound with no marketing authorisation in any country, and is prohibited at all times, even though the List does not name it. Registered athletes (ADAMS) check the current version of the List before any decision. Pancragen as a reagent is not registered as a medicine in the EU, US or other jurisdiction; lack of EMA/FDA authorization as a medicinal product and EFSA as a dietary supplement ingredient.

Commercial equivalent Superfort (Pancramin) is distributed as a product in Russia – this does not change the status of Pancragen reagent, which is intended for laboratory research only and is not an insulin or a drug for diabetes.

Summary

Pancragen 20 mg provides a synthetic short regulatory peptide (traditionally linked to the tetrapeptide Lys-Glu-Asp-Trp, KEDW) from the family of tissue-specific bioregulators of the Vladimir Khavinson school (St. Petersburg Institute of Bioregulation and Gerontology), Endogenic line – in the form of a vial with a lyophilisate for self-reconstitution. The peptide is attributed to the pancreas (islet of Langerhans cells and exocrine cells), and the conceptual assumption is the modulation of pancreatic cell gene expression by a short peptide – a hypothesis covering four main threads: tissue-specific bioregulation of the pancreatic cell, modulation of secretory function in models (digestive enzymes, glycemic regulation in the research context), antioxidant/anti-inflammatory effects in the tissue pancreas and supporting cell regeneration and protection in models.

The whole concept remains mainly developed by the Russian school of science and is characterized by limited independent replication – data comes from cellular and animal models, without large randomized clinical trials. The Pancragen research reagent must be distinguished from the commercial preparation Superfort (Pancramin, Cytomax, Russia), and above all remember that the peptide is a bioregulator it is not insulin or a cure for diabetes.

The vial format allows the researcher to select any working concentration and ensures long shelf life of the lyophilisate before dissolution. Regulatory Status – Research Use Only; WADA status: class S0 (non-approved substances), prohibited at all times. The sequence of each batch requires confirmation with the COA. The broader context of the Khavinson family of bioregulators and organ-related peptides includes, among others: telomeric Epithalon 10mg; Some of the materials from this line are also available in the form of: peptides in capsules.

Bibliography

  1. Khavinson VKh (2002). Peptides and Aging. PubMed
  2. Khavinson VK, Popovich IG, Linkova NS, et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. PubMed
  3. Kuznik BI, Khasanova NB, Ryzhak GA, et al. (2020). The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. PubMed
  4. Anisimov VN, Khavinson VKh (2010). Peptide bioregulation of aging: results and prospects. PubMed
  5. Chalisova NI, Linkova NS, Zhekalov AN, et al. (2015). Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. PubMed

Chemical reagent Research Use Only. Pancragen 20 mg (Endogenic line) in the Pro-Body catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment. Pancragen is a short pancreatic bioregulator peptide of the Khavinson school, traditionally associated with the tetrapeptide Lys-Glu-Asp-Trp (KEDW) – sequence and mass confirmed by mass spectrometry in the COA of the batch conclusively determine the identity.

Pancragen it is not registered as a medicine in the EU or the US, it is not insulin or a cure for diabetes and does not replace medical consultation; it should be distinguished from Suprefort (Pancramin, Cytomax line). The information in the description is of an educational and scientific nature and refers to observations reported in preclinical literature – it does not constitute medical advice or administration instructions.